Isabel Mur

Isabel Mur

Auto-generated profile, based on publicly available information

Isabel Mur

Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
MGMaría Del Mar Gutierrez
María Del Mar Gutierrez
IMIsabel Mur
Isabel Mur
MMMaría Gracia Mateo
María Gracia Mateo
FVFrancesc Vidal
Francesc Vidal
PDPere Domingo
Pere Domingo
When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed.Data from observational...

4 January 2021 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
NCNoemí Corbacho
Noemí Corbacho
IMIsabel Mur
Isabel Mur
MMMaria Molas Morena
Maria Molas Morena
FVFrancesc Vidal
Francesc Vidal
PDPere Domingo
Pere Domingo
Summary Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment strategies are similar. However, there are CVR factors particular to PLWH, which need separate consideration. These factors are those HIV-dependent, those related to HIV-derived consequences, and combination antiretroviral therapy (cART)-dependent. Areas covered: In this review, the authors discuss the management of CVD in PLWH, with a special interest in pharmacological treatment and drug-drug interactions with cART. Expert opinion: In recent years, we have witnessed a decreased CVD morbidity and mortality in PLWH, which probably reflects an improvement in the management of CVR factors and CVD in these patients, partially thanks to new developments in antiretroviral therapy. Therefore, although there is still room for improvement, at present, the old desideratum of equalling PLWH and the general population in terms of CVD incidence and prognosis is a little closer.